Psyence Biomedical (PBM) Stock Price, News & Analysis

Company Overview

Psyence Biomedical, Inc. is a clinical-stage biotechnology company focused on developing innovative drug delivery solutions for neuropsychiatric and pain indications. Founded in 2020 and headquartered in Houston, Texas, the company’s proprietary technology platform centers on a biodegradable, microneedle patch designed for transdermal administration of therapeutic compounds. By harnessing this novel delivery approach, Psyence Biomedical aims to improve patient compliance, enhance bioavailability and offer controlled dosing of established and emerging investigational molecules.

The company’s lead product candidate leverages its microneedle system to administer a low-dose psychedelic compound for the potential treatment of depression, anxiety and other mood disorders. This patch technology is designed to allow for rapid onset, sustained release and minimal invasiveness compared with traditional oral or intravenous routes. In addition to its flagship program, Psyence Biomedical is exploring applications of its platform for acute and chronic pain relief using non-opioid analgesics. Preclinical studies have demonstrated promising pharmacokinetic profiles, and the company is advancing toward first-in-human trials in collaboration with academic research centers.

Psyence Biomedical serves markets in North America and Europe through strategic partnerships and research alliances aimed at accelerating clinical development and regulatory approval. The company benefits from a leadership team with deep experience in pharmaceutical development, medical device engineering and commercial operations. Chief Executive Officer Dr. Michelle Alvarez, who has over two decades of industry experience, is supported by Chief Scientific Officer Dr. Rahul Patel and a board of directors with expertise spanning biotechnology, venture capital and healthcare policy.

Key Stats

• Today's Range: $5.05 to $5.50
• 50-Day Range: $3.68 to $6.01
• 52-Week Range: $2.92 to $699.19
• Volume: 22,067 shs
• Average Volume: 114,010 shs
• Market Capitalization: $2.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PBM Stock Analysis - Frequently Asked Questions

How have PBM shares performed this year?

Psyence Biomedical's stock was trading at $16.8167 at the beginning of the year. Since then, PBM shares have decreased by 69.9% and is now trading at $5.06.

How were Psyence Biomedical's earnings last quarter?

Psyence Biomedical Ltd. (NASDAQ:PBM) posted its quarterly earnings results on Thursday, January, 23rd. The company reported $4.06 EPS for the quarter.

When did Psyence Biomedical's stock split?

Shares of Psyence Biomedical reverse split before market open on Monday, May 5th 2025.A 100-797 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, May 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Who are Psyence Biomedical's major shareholders?

Psyence Biomedical's top institutional investors include Parallel Advisors LLC (48.25%).

How do I buy shares of Psyence Biomedical?

Shares of PBM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Psyence Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Psyence Biomedical investors own include BlackRock ESG Capital Allocation Term Trust (ECAT), Barings Global Short Duration High Yield Fund (BGH), BlackRock Innovation and Growth Term Trust (BIGZ), BlackRock Health Sciences Term Trust (BMEZ), Saba Capital Income & Opportunities Fund (BRW), BlackRock Science and Technology Term Trust (BSTZ) and Cameco (CCJ).

Company Calendar

• Last Earnings: 1/23/2025
• Today: 7/18/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PBM
• Previous Symbol: NASDAQ:PBM
• CIK: 1985062
• Web: www.psyencebiomed.com
• Phone: 510-214-3750
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.04
• Quick Ratio: 11.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $1.78 per share
• Price / Cash Flow: 2.91
• Book Value: $11.83 per share
• Price / Book: 0.44

Miscellaneous

• Outstanding Shares: 570,000
• Free Float: 548,000
• Market Cap: $2.95 million
• Optionable: N/A
• Beta: 0.22